Correlation Between Neuropace and Accelerate Diagnostics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Neuropace and Accelerate Diagnostics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Neuropace and Accelerate Diagnostics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Neuropace and Accelerate Diagnostics, you can compare the effects of market volatilities on Neuropace and Accelerate Diagnostics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Neuropace with a short position of Accelerate Diagnostics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Neuropace and Accelerate Diagnostics.

Diversification Opportunities for Neuropace and Accelerate Diagnostics

-0.05
  Correlation Coefficient

Good diversification

The 3 months correlation between Neuropace and Accelerate is -0.05. Overlapping area represents the amount of risk that can be diversified away by holding Neuropace and Accelerate Diagnostics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Accelerate Diagnostics and Neuropace is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Neuropace are associated (or correlated) with Accelerate Diagnostics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Accelerate Diagnostics has no effect on the direction of Neuropace i.e., Neuropace and Accelerate Diagnostics go up and down completely randomly.

Pair Corralation between Neuropace and Accelerate Diagnostics

Given the investment horizon of 90 days Neuropace is expected to generate 2.53 times more return on investment than Accelerate Diagnostics. However, Neuropace is 2.53 times more volatile than Accelerate Diagnostics. It trades about 0.31 of its potential returns per unit of risk. Accelerate Diagnostics is currently generating about -0.18 per unit of risk. If you would invest  638.00  in Neuropace on August 29, 2024 and sell it today you would earn a total of  382.00  from holding Neuropace or generate 59.87% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Neuropace  vs.  Accelerate Diagnostics

 Performance 
       Timeline  
Neuropace 

Risk-Adjusted Performance

7 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Neuropace are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of rather unsteady fundamental indicators, Neuropace exhibited solid returns over the last few months and may actually be approaching a breakup point.
Accelerate Diagnostics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Accelerate Diagnostics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's fundamental indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Neuropace and Accelerate Diagnostics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Neuropace and Accelerate Diagnostics

The main advantage of trading using opposite Neuropace and Accelerate Diagnostics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Neuropace position performs unexpectedly, Accelerate Diagnostics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Accelerate Diagnostics will offset losses from the drop in Accelerate Diagnostics' long position.
The idea behind Neuropace and Accelerate Diagnostics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Other Complementary Tools

Bonds Directory
Find actively traded corporate debentures issued by US companies
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm